Narrative Review: Update on the Molecular Diagnosis of Fragile X Syndrome

• Published in: International journal of molecular sciences Vol. 24; no. 11; p. 9206
• Main Authors: Ciobanu, Cristian-Gabriel, Nucă, Irina, Popescu, Roxana, Antoci, Lucian-Mihai, Caba, Lavinia, Ivanov, Anca Viorica, Cojocaru, Karina-Alexandra, Rusu, Cristina, Mihai, Cosmin-Teodor, Pânzaru, Monica-Cristina
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 24-05-2023; MDPI
• Subjects: Alleles; Ataxia; Autism; Care and treatment; Cell culture; Diagnosis; DNA Methylation; Fragile X Mental Retardation Protein - genetics; Fragile X Mental Retardation Protein - metabolism; Fragile X syndrome; Fragile X Syndrome - diagnosis; Fragile X Syndrome - genetics; Gene mapping; Gene Silencing; Genes; Genetic engineering; Genomes; Genomics; Genotype & phenotype; Humans; Intellectual disabilities; Ions; long read; Methylation; Mosaicism; Mutation; New technology; Oxford Nanoporesequencing; PacBio sequencing; Polymerase chain reaction; Proteins; Review; Trinucleotide Repeats; United Kingdom; Romania; long read; Oxford Nanoporesequencing; PacBio sequencing; methylation; fragile X syndrome
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24119206

The diagnosis and management of fragile X syndrome (FXS) have significantly improved in the last three decades, although the current diagnostic techniques are not yet able to precisely identify the number of repeats, methylation status, level of mosaicism, and/or the presence of AGG interruptions. A high number of repeats (>200) in the fragile X messenger ribonucleoprotein 1 gene (
) results in hypermethylation of promoter and gene silencing. The actual molecular diagnosis is performed using a Southern blot, TP-PCR (Triplet-Repeat PCR), MS-PCR (Methylation-Specific PCR), and MS-MLPA (Methylation-Specific MLPA) with some limitations, with multiple assays being necessary to completely characterise a patient with FXS. The actual gold standard diagnosis uses Southern blot; however, it cannot accurately characterise all cases. Optical genome mapping is a new technology that has also been developed to approach the diagnosis of fragile X syndrome. Long-range sequencing represented by PacBio and Oxford Nanopore has the potential to replace the actual diagnosis and offers a complete characterization of molecular profiles in a single test. The new technologies have improved the diagnosis of fragile X syndrome and revealed unknown aberrations, but they are a long way from being used routinely in clinical practice.